AstraZeneca enters into agreement with Perrigo for rights to Entocort in the US Divestment further sharpens focus on three main therapy areas Agreement follows ex-US divestment of Entocort in July 2015 23 November 2015 AstraZeneca today announced that it has entered into an agreement with Perrigo Company plc for the divestment of US rights […]
Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Leadership representing the 2018 Manny Award agency and network winners and finalists share their views on various healthcare industry trends and developments.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
Current health systems built to evaluate and pay for traditional drugs are going to struggle with gene and other unusual therapies – but manufacturers can take steps before launch to define how manufacturers assess and value these new products.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
A recent study of DTC advertising appearing in the Journal of General Internal Medicine concluded that few broadcast ads are compliant with FDA’s guidelines. The reality, though, might not be so cut and dried.
As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.
On Oct. 28, 2016, my mother, Joan Biamonte, died of complications from metastatic carcinoma of the lung. Despite having her original tumor characterized and going through a regimen of chemotherapy allegedly tailored to her tumor type, her cancer proliferated and spread into her liver and brain.
After three weeks of speculation New York-based Pfizer Inc. (PFE) announced today that it was merging with Dublin, Ireland-based Allergan plc (AGN). Board members for both companies unanimously voted Sunday to approve the deal, which will have a total enterprise value of about $160 billion. The deal will be a stock transaction of about […]
Swiss drugmaker Roche released on Monday what it called encouraging early data on cancer drug atezolizumab in combination therapy for treating a form of advanced melanoma. A phase Ib study of atezolizumab (MPDL3280A), used in combination with the BRAF inhibitor Zelboraf for previously untreated BRAFV600 mutation-positive inoperable or metastatic melanoma, showed adverse events were […]
Drug companies have brought a host of expensive new medicines to market in the United States and Europe this year, figures show, another bumper haul for an industry often accused of over-charging. Drug prices are set to be a major issue in the run-up to the U.S. presidential election next year, with Democratic candidate Hillary […]
Yesterday’s announcement by the U.S. Treasury Department of rules changes to make tax inversions more difficult, might stop the pending Pfizer Inc. (PFE)-Allergan, Inc. (AGN) deal, but insiders are indicating it may be structured differently to avoid those changes. Predominantly, there is speculation that instead of Pfizer acquiring Allergan, the deal will be structured in […]
French drugmaker Sanofi and Britain’s AstraZeneca said on Friday they had agreed a direct exchange of 210,000 chemical compounds from their respective libraries in a new twist on the drive to boost open innovation. In a bid to increase the number of leads for new medicines, and save both time and money, pharmaceutical companies are […]
LAVAL, Quebec – Embattled Valeant Pharmaceuticals International Inc. (VRX) is offering stock and cash incentives in an effort to keep key employees from jumping to another company, Reuters reported this morning. A Valeant spokesperson told Reuters that approximately 70 employees “below the executive level” have been offered incentives to stay with the company. It is […]
Amgen’s new injectable cholesterol drug Repatha has been turned down for use on Britain’s state health service, underscoring a worldwide debate about the value of such pricey medicines. Repatha belongs to a potent new class of drugs known as PCSK9 inhibitors that are extremely effective at lowering “bad” LDL cholesterol. But the National Institute for […]
Global spending on medicines will reach $1.4 trillion in 2020, driven by increased healthcare access in emerging markets and high-priced new drugs for cancer and other diseases, according to a forecast by IMS Health released on Wednesday. That is up from about $1.07 trillion this year, representing a compound annual growth rate of 4 to […]
The American Medical Association on Tuesday called for a ban on advertising prescription drugs and medical devices directly to consumers, saying the ads drive patients to demand expensive treatments over less costly ones that are also effective. The influential doctors’ group said the new policy reflects physicians’ concerns that marketing spending on a proliferation of […]